RG 6496
Alternative Names: RG-6496Latest Information Update: 10 Dec 2025
At a glance
- Originator Roche
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Huntington's disease
Most Recent Events
- 19 Nov 2025 Phase-I clinical trials in Huntington's disease in New Zealand (Intrathecal) (NCT07246941)